Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 3:00 AM
Ignite Modification Date: 2025-12-25 @ 3:00 AM
NCT ID: NCT02774733
Eligibility Criteria: Inclusion Criteria: 1. The patients were diagnosed with T2DM according to the guidelines of the American Diabetes Association; 2. No smoking history, pulmonary disease nor pulmonary infection within a fortnight; 3. Did not have hepatopathy, nephropathy, and gastrointestinal disease; and 4. Likely to have good compliance and able to visit our hospital for periodic assessments. Exclusion Criteria: 1. T1DM, gestation and lactation; 2. Renal inadequacy, a serum creatinine \>132 µmol/L (male), or a serum creatinine \>123 µmol/L (female); 3. hypohepatia, the liver enzyme was two times higher than normal; 4. Intensive care with insulin treatment; 5. The patients combinated with DR and hypertension (antihypertensive drugs were used); 6. Patients with other eye conditions that could affect the blood flow, such as high degree myopia, maculopathy of any origin, glaucoma, and those with a history of laser treatment or introacular surgery; 7. New York Heart Association class III or IV heart failure, a history of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within 6 months; 8) Cholesterol-lowering drugs can not control the blood-fat (TC \> 250 mg/dl, HDL-C \< 30 mg/dL, LDL-C \> 170 mg/dl, TG \> 200 mg/dl) adequately; and 9\) Use of systemically injected glucocorticoids within 3 months prior to our study.
Healthy Volunteers: True
Sex: ALL
Minimum Age: 34 Years
Maximum Age: 68 Years
Study: NCT02774733
Study Brief:
Protocol Section: NCT02774733